Possible New Immunotherapy Treatment for Acute Myeloid Leukemia (AML)

New research has identified a novel immunotherapy for acute myeloid leukemia. The study, published on October 2, 2023 in Nature Cancer, describes a T-cell receptor that recognizes a mutation shared amongst a subgroup of patients with the disease. The results provide hope for new and effective treatment using T cells equipped with the therapeutic T cell receptor, “programmed” to kill the leukemia cells. The open-access article is titled “A T Cell Receptor Targeting a Recurrent Driver Mutation in FLT3 Mediates Elimination of Primary Human Acute Myeloid Leukemia in Vivo.”